The net outflow of 12 shares, including Zhongsheng Pharmaceutical and China Pharmaceutical, exceeded 100 million yuan

【Pharmaceutical Network Pharmaceutical Stock Market】 On December 27, the Shanghai Composite Index rose 0.
98%.

From the perspective of funds, the main funds of the two cities had a net outflow of 7.
244 billion yuan
throughout the day.
There are 16 industries with a net outflow of main funds, and the pharmaceutical and biological industry has the largest net outflow of main funds, with a net outflow of 5.
602 billion yuan
throughout the day.
Among the net outflow of funds from the pharmaceutical and biological industry, there were 12 stocks with a net outflow of more than 100 million yuan, including Zhongsheng Pharmaceutical, China Pharmaceutical, Hanyu Pharmaceutical, Hengrui Pharmaceutical, and Yiling Pharmaceutical, with net outflows of 663 million yuan, 492 million yuan, 346 million yuan, 305 million yuan and 270 million yuan
respectively.
It is reported that Zhongsheng Pharmaceutical announced that the daily closing price decline deviation of the company's stock in three consecutive trading days on December 23, December 26 and December 27, 2022 accumulated more than 20%, which is an abnormal
fluctuation in stock trading 。 According to the announcement, ZSP1273 tablets, a class of innovative drugs used by Zhongsheng Pharmaceutical for the treatment of simple influenza A in adults, are in the phase III clinical trial stage, and the company will continue to pay attention to the domestic influenza A epidemic dynamics, maintain close contact and communication with various clinical research centers and cooperation, increase the recruitment and screening of influenza A subjects, actively promote enrollment, and take strong measures to promote the process of phase III clinical trial
of ZSP1273 tablets 。 The company's 3CL protease inhibitor RAY1216, its randomized, double-blind, placebo-controlled phase III clinical research protocol for the treatment of mild and common SARS-CoV-2 infection patients has obtained the rapid review approval of the clinical trial of the Medical Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University, and the project is approved for development, and a phase III clinical study
is currently being carried out.
It is reported that China National Pharmaceutical rebounded rapidly intraday on December 27, rising more than 2% in 5 minutes, and as of 10:17, it was reported at 19.
06 yuan, with a transaction of 2.
062 billion yuan and a turnover rate of 7.
12%.

In addition, China Pharmaceutical Financing and Securities Lending Information shows that on December 27, 2022, the net repayment of financing was 12.
1498 million yuan, and the financing balance was 1.
017 billion yuan, down 1.
11%
from the previous day.
In terms of financing, the financing bought 271 million yuan on the same day, the financing repaid 283 million yuan, and the net repayment of financing was 12.
1498 million yuan
.
In terms of securities lending, 211,300 shares were sold and 40,600 shares were repaid, with a margin of 1,876,800 shares and a balance of 35,472,400 yuan
.
The total balance of margin and securities lending was 1.
053 billion yuan
.
On December 27, Hanyu Pharmaceutical was stopped by "20CM"
.
Data show that as of the close of the day, Hanyu Pharmaceutical's stock price was 17.
2 yuan, down 20%, and the turnover rate was 10.
9%.

The market value fell to 15.
771 billion yuan after evaporating by 3.
943 billion yuan
.
According to public information, Hanyu Pharmaceutical is an enterprise
specializing in the research and development, production and sales of peptide drugs.
The main products include peptide APIs, customized peptides, beauty peptides, peptide preparations and other series
.
The company's stock price rose about 1.
5 times in the early stage, but the company's stock price rose sharply due to the promotion of the peptide drug HY3000 nasal spray developed in cooperation with the Institute of Microbiology of the Chinese Academy of
Sciences.
On December 27, Hanyu Pharmaceutical said on the interactive platform that the multi-center randomized double-blind phase II clinical trial of HY3000 nasal spray is advancing rapidly, and after enrollment and follow-up, clinical data will be unblinded, and clinical indicators
such as the protective power of this product will be statistically analyzed.
The expansion of APIs and formulations of this product is also progressing
steadily as planned.
As of the close on December 27, 2022, Hengrui Pharmaceutical closed at 37.
07 yuan, down 1.
3%, with a turnover rate of 0.
5%, a volume of 320,100 lots and a turnover of 1.
188 billion yuan
.
In addition, Hengrui Pharmaceutical's financing and securities lending information shows that in terms of financing, the financing bought 67.
7708 million yuan on the same day, the financing repaid 92.
0232 million yuan, and the net repayment of financing was 24.
2524 million yuan
.
In terms of securities financing, 81,400 shares were sold and 256,700 shares were repaid, with a margin of 3,056,900 shares and a balance of 113 million yuan
.
The balance of margin and securities lending was 4.
483 billion yuan
.
Data show that Hengrui Pharmaceutical achieved main revenue of 15.
945 billion yuan in the first three quarters of this year, and net profit attributable to the parent of 3.
173 billion yuan
.
A total of 20 institutions have rated the stock in the past 90 days, with 16 Buy ratings and 4 Overweight ratings; The average institutional target price over the past 90 days is 45.
21
.
On December 27, Yiling Pharmaceutical fell rapidly intraday, and its stock price fell by more than 8%
at one point.
The company's turnover has expanded sharply, and the current one-hour trading volume has exceeded 2.
4 billion yuan, close to the level
of the previous trading day.
On the market, anti-epidemic drug varieties fell collectively
.
In addition to the above enterprises, the net outflow of Xinhua Pharmaceutical, Jiuan Medical, Shanghai Kaibao, China Resources Shuanghe, CanSino, Wanfu Biotech and Fosun Pharma was 250 million yuan, 166 million yuan, 160 million yuan, 155 million yuan, 149 million yuan, 136 million yuan and 129 million
yuan respectively.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.